Eli Lilly notches another positive baricitinib eczema trial, but has Dermira made it obsolete?
Entering today, most of what you needed to know about Eli Lilly’s JAK inhibitor baricitinib could be found in two places:
In the FDA-mandated, 1 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
